Florence Lefresne

782 total citations
26 papers, 491 citations indexed

About

Florence Lefresne is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Florence Lefresne has authored 26 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Florence Lefresne's work include Prostate Cancer Treatment and Research (13 papers), Cancer Treatment and Pharmacology (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Florence Lefresne is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Cancer Treatment and Pharmacology (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Florence Lefresne collaborates with scholars based in France, United Kingdom and Germany. Florence Lefresne's co-authors include Laurent Nguyen, Jan B. Vermorken, Roger Stupp, Hugues Bourgeois, P. Fumoleau, G. Dark, Andrea A. Jones, J.M. Tourani, C. Puozzo and R. Bugat and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

Florence Lefresne

24 papers receiving 487 citations

Peers

Countries citing papers authored by Florence Lefresne

Since Specialization

Citations

This map shows the geographic impact of Florence Lefresne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Lefresne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Lefresne more than expected).

Fields of papers citing papers by Florence Lefresne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Lefresne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Lefresne. The network helps show where Florence Lefresne may publish in the future.

Co-authorship network of co-authors of Florence Lefresne

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Lefresne. A scholar is included among the top collaborators of Florence Lefresne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Lefresne. Florence Lefresne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer 2024 ·British Journal of Urology ·Pär Stattin, (unknown), Xiwu Lin, Florence Lefresne, Sabine Brookman‐May, Suneel Mundle, (unknown), Dina Gifkins, David Robinson, Johan Styrke, Hans Garmo	0
2	Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study 2023 ·European Journal of Cancer ·Axel S. Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, (unknown), Andrea Juliana Gomes, Álvaro Juárez Soto, Robert Given, Sabine Brookman‐May, Suneel Mundle, Sharon McCarthy, Hirotsugu Uemura, Simon Chowdhury, Kim N., Anders Bjartell	14
3	Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study 2022 ·International Journal of Urology ·Hirotsugu Uemura, Gaku Arai, Hiroji Uemura, Hiroyoshi Suzuki, (unknown), (unknown), (unknown), Florence Lefresne, Sharon McCarthy, Suneel Mundle, Jin He, Kim N.	12
4	Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial 2021 ·Annals of Oncology ·Anuradha Jayaram, Anna Wingate, Daniel Wetterskog, Graham Wheeler, Cora N. Sternberg, Robert J. Jones, Alfredo Berruti, Florence Lefresne, Marjolein Lahaye, Shibu Thomas, Michael Gormley, (unknown), (unknown), (unknown), Axel S. Merseburger, Bertrand Tombal, Deborah Ricci, G. Attard	36
5	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry 2021 ·Targeted Oncology ·Anders Bjartell, Nicolaas Lumen, Pablo Maroto, Thomas Paiss, F. Gómez-Veiga, Alison Birtle, Gero Kramer, Ewa Kalinka‐Warzocha, Dominique Spaëth, Susan Feyerabend, В. Б. Матвеев, Florence Lefresne, Martin Lukáč, Robert Wapenaar, Luís Costa, Simon Chowdhury	11
6	MP24-08 RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN 2021 ·The Journal of Urology ·Anders Bjartell, Neeraj Agarwal, Lawrence I. Karsh, Axel S. Merseburger, Andrea Juliana Gomes, Álvaro Juárez Soto, Robert Given, Amitabha Bhaumik, Sabine Brookman‐May, Florence Lefresne, Suneel Mundle, Sharon McCarthy, Shibu Thomas, Justin Lucas, Clemente Aguilar-Bonavides, Hirotsugu Uemura, Simon Chowdhury, Kim N.	0
7	Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). 2021 ·Journal of Clinical Oncology ·Neeraj Agarwal, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Gomes, Robert Given, Álvaro Juárez, Axel S. Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Sabine Brookman‐May, Suneel Mundle, Sharon McCarthy, Florence Lefresne, Shiva Dibaj, Katherine B. Bevans, Kim N., (unknown)	3
8	Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa) 2021 ·European Urology ·S. Chowdhury, Anders Bjartell, (unknown), Byunghoon Chung, Hiroji Uemura, (unknown), Mustafa Özgüroğlu, Andrea Juliana Gomes, Álvaro Juárez Soto, Robert Given, Suneel Mundle, Amitabha Bhaumik, (unknown), Florence Lefresne, Shane McCarthy, (unknown), Neeraj Agarwal	2
9	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry 2020 ·Targeted Oncology ·Simon Chowdhury, Anders Bjartell, Nicolaas Lumen, Pablo Maroto, Thomas Paiss, F. Gómez-Veiga, Alison Birtle, Gero Kramer, Ewa Kalinka‐Warzocha, Dominique Spaëth, Susan Feyerabend, Vsevolod Matveev, Florence Lefresne, Martin Lukáč, Robert Wapenaar, Luís Costa	49
10	Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study 2019 ·European Urology ·Antoine Thiery-Vuillemin, Mads Hvid Poulsen, É. Lagneau, Guillaume Ploussard, Alison Birtle, (unknown), (unknown), Elias Pintus, Redas Trepiakas, Florence Lefresne, Martin Lukáč, Suzy Van Sanden, (unknown), Alison Reid	43
11	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer 2019 ·JAMA Oncology ·Gerhardt Attard, Axel S. Merseburger, Wiebke Arlt, Cora N. Sternberg, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Lajos Géczi, Florence Lefresne, Marjolein Lahaye, (unknown), (unknown), Sue Chua, Robert J. Jones, Bertrand Tombal	35
12	Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours 2013 ·Cancer Chemotherapy and Pharmacology ·Jean‐Pierre Delord, J.M. Tourani, Florence Lefresne, Aurélie Pétain, Jean-Christophe Pouget, Alain Ravaud	2
13	A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines 2013 ·The Breast Journal ·Mario Campone, (unknown), (unknown), (unknown), (unknown), F. Mefti, (unknown), Florence Lefresne, (unknown), Jacek Jassem	14
14	Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors. 2009 ·PubMed ·Jean‐Pierre Delord, C. Puozzo, Florence Lefresne, R. Bugat	26
15	Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours 2007 ·Cancer Chemotherapy and Pharmacology ·Hugues Bourgeois, Jan B. Vermorken, G. Dark, Andrew Jones, P. Fumoleau, Roger Stupp, J.M. Tourani, Étienne Brain, Laurent Nguyen, Florence Lefresne, C. Puozzo	32
16	A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma 2007 ·Lung Cancer ·Yuh‐Min Chen, Chong‐Jen Yu, James Chih‐Hsin Yang, Reury-Perng Perng, Chun‐Ming Tsai, Jen-Fu Shih, Ann‐Lii Cheng, Florence Lefresne, (unknown), Jean-Christophe Pouget, Pan‐Chyr Yang	12
17	First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II 2007 ·Jean‐Pierre Delord, Jaafar Bennouna, Véronique Dièras, Mario Campone, Florence Lefresne, (unknown), Jean‐Yves Douillard	3
18	Vinorelbine alternating oral and intravenous plus carboplatinin advanced non-small-cell lung cancer: results of a multicentre phase II study 2004 ·Annals of Oncology ·Mary O’Brien, Aleksandra Szczęsna, (unknown), Petr Zatloukal, Tim Eisen, Wolfgang Hartmann, Peter Kasan, (unknown), Florence Lefresne	17
19	Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer 2003 ·Annals of Oncology ·Jacek Jassem, P. Kosmidis, Rodryg Ramlau, (unknown), (unknown), Jean-Luc Breton, Pierre-Luc Etienne, C Seebacher, M Grivaux, (unknown), D. Aubert, Florence Lefresne	34
20	P-544 Final results of a phase I study with navelbine (NVB) oral in combination with cisplatin (C), evaluating two different schedules in advanced non-small cell lung cancer (NSCLC) patients 2003 ·Lung Cancer ·Yuh‐Min Chen, James Chih‐Hsin Yang, Chong‐Jen Yu, Reury-Perng Perng, C.-M. Tsai, Jen-Fu Shih, Ann‐Lii Cheng, D. Aubert, Florence Lefresne, Pan‐Chyr Yang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact